Objective: We used resting-state functional connectivity (rsFC) to evaluate the integrity of the neural circuits associated with primary and secondary rewards in bipolar disorder (BD) with different mood phases.Methods: Sixty patients with BD [21 patients with depressive episode of BD (BDD) and 41 patients with maniac episode of BD (BDM)] and 42 healthy controls (HCs) underwent resting-state functional magnetic resonance imaging. rsFC was assessed using region of interest-wise analyses.Results: Attenuation of rsFC at the orbitofrontal cortex (OFC) and the left ventral striatum (LVS) was observed in the secondary reward circuit of patients with BD compared to that of HCs. Among BDD, BDM and HCs, the rsFC between OFC and LVS in BDM was intermediate, while the rsFC between OFC and right ventral striatum/right amygdala in BDM was the highest; the corresponding rsFC values in BDD were the lowest. Furthermore, a positive correlation was found between rsFC and Young Mania Rating Scale scores in BDM.Conclusions: This study suggests that there may be an abnormal rsFC between OFC and LVS in the second reward of patients with BD and the discrepant patterns of rsFC may exist between different mood states in patients with BD.
23 October 2022 in Journal of Psychosomatic Research
Purpose: This study aimed to investigate the combined effects of dose, age, sex, body weight, and smoking on plasma concentrations of olanzapine (OLA) and N-desmethyl olanzapine (DMO) in Chinese inpatients with schizophrenia. Methods: A retrospective study including 185 inpatients was conducted. The steady-state plasma concentrations of OLA (COLA) and DMO (CDMO) were measured using high-performance liquid chromatography-tandem mass spectrometry. The combined effects of dose, age, sex, body weight, and smoking on COLA and CDMO were evaluated. Findings: Multiple linear regression analyses revealed that dose, age, body weight, and smoking had significant effects on COLA and CDMO in inpatients with schizophrenia treated with OLA. The dose was the most important determinant of COLA and CDMO and was positively correlated with both. Furthermore, smokers exhibited a significantly lower COLA and COLA + DMO, whereas higher body weight led to the reduction of COLA, CDMO, and COLA + DMO. Advanced age was associated with lower CDMO. Implications: These results suggest that dose, age, body weight, and smoking have a significant influence on the plasma concentration of OLA and its metabolite DMO. Clinicians should consider the combined effects when prescribing OLA to patients with schizophrenia.
Objectives: The aim of the present study was to investigate a potential relationship between metabolic parameters and steady-state plasma concentrations of olanzapine (OLA) and its metabolite, 4-N'-desmethyl-olanzapine (DMO) in patients with schizophrenia taking therapeutic doses.Methods: A total of 352 inpatients, diagnosed with schizophrenia according to the DSM-V criteria and treated with OLA, were investigated. The plasma concentrations of OLA and DMO were measured by high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Fasting blood samples were measured for insulin, glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), C-reactive protein (CRP) and homocysteine, and differences in these parameters were investigated in relation to plasma concentrations of OLA and DMO.Results: Lower plasma DMO concentrations were associated with higher glucose and TG levels and homeostasis model assessment of insulin resistance (HOMA-IR), while higher plasma OLA concentrations were associated with higher CRP and homocysteine levels in the OLA-treated patients with schizophrenia.Conclusion: These results demonstrate that OLA and its metabolite DMO may have different effects on OLA-induced metabolic abnormalities. DMO might have a counteracting effects on glucose-insulin homeostasis and lipid metabolic abnormalities, which suggests that regular measure of various metabolic parameters and drug monitoring on both OLA and DMO are recommended in OLA-treated patients with schizophrenia.
Objective: Although non-suicidal self-injury (NSSI) behaviors are particularly prevalent among adolescent outpatients with major depressive disorder (MDD), few studies have investigated the sex differences in this population. Therefore, this study aimed to investigate sex differences in the prevalence and risk factors of NSSI among adolescent outpatients with MDD. Methods: In total, 284 adolescent outpatients who met the DSM-V diagnostic criteria for MDD were recruited for this cross-sectional study. A self-designed questionnaire, the Children’s Depression Inventory (CDI), Chinese version of the Functional Assessment of Self-Mutilation (CFASM), Pittsburgh Sleep Quality Index (PSQI), and Adolescent Self-Rating Life Events Checklist (ASLEC) were employed to assess participants’ socio demographic factors, depressive symptoms, NSSI behaviors, sleep quality, and stressful life events, respectively. Results: The prevalence of NSSI behaviors was significantly higher in female adolescents than in male adolescents. Notably, female adolescents demonstrated significantly higher NSSI functioning scores, NSSI frequency, and CDI scores than male adolescents. Regression analysis showed that among female adolescents, higher PSQI and ASLEC scores were identified as significant risk factors for NSSI behaviors, with the frequency of NSSI positively correlated with ASLEC scores. However, these associations were not observed in males. Conclusion: NSSI is more prevalent in female adolescent outpatients with MDD than male outpatients with MDD. Further, there are significant sex differences in the risk factors associated with NSSI, suggesting that sex differences should be considered when developing prevention and intervention strategies for coexisting NSSI behaviors among adolescent outpatients with MDD.